comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 20:05:54 - browse：2

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： How to pay for weight loss drugs and save Medicare

WSS

BIO selects John Crowley as new CEO

Despite FDA concern, risk that CAR

Pediatric cancer treatments threatened by a new FDA policy

Key House Republican on health care plans exit from Congress

Vaccine advisory panel ACIP left half staffed by HHS

Flagship Pioneering launches a new biotech in two countries

focus

comprehensive

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

J&J to emphasize cancer drugs, stop much of its vaccine research

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cigna, Humana reportedly in talks to merge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Bright Health sells Medicare Advantage business to Molina

Key House Republican on health care plans exit from Congress

Drug repurposing or repositioning? The language matters

Gilead might be held responsible for not developing a drug

explore

Doctors' information doesn't help them choose wisely when sick

Medical mystery: When a cough is not just a cough

Fetal surgery at risk from Dobbs and new abortion restrictions

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Private equity deals in Medicare Advantage declines

entertainment

explore

hotspot

hotspot